Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

As millions of Americans experience the benefits of weight loss through the use of GLP-1 medications, some orthopedic experts are still torn on the potential effects the medications will have for ...

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine ...

In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Websites that sell compounded GLP-1 RAs often partially inform or misinform consumers, including with respect to US FDA approval.

Robert F. Kennedy Jr. sounded concern on the GRAS process and claimed GLP-1s are “miracle drugs” but fell short on the drugs ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...